|
|
 |
|
Viewing report
|
|
|
|
Functional Proteomics and Nanotechnology-Based Microarrays
Pan Stanford Publishing Pte. Ltd, June 2011, Pages: 308
This volume introduces in a coherent and comprehensive fashion the Pan Stanford Series on Nanobiobiotechnology by defining and reviewing the major sectors of Nanobiotechnology and Nanobiosciences with respect to the most recent developments. Nanobiotechnology indeed appears capable of yielding a scientific and industrial revolution along the routes correctly foreseen by the numerous programs on Nanotechnology launched over the last decade by numerous Councils and Governments worldwide, beginning in the late 1995 by the Science and Technology Council in Italy and by the President Clinton in USA and ending this year with President Putin in Russian Federation.
The aims and scope of the Series and of this Volume are to cover the basic principles and main applications of Nanobiotechnology as an emerging field at the frontiers of Biotechnology and Nanotechnology. The publishing policy of the Series consists of at least one volume per year up to two per year with the title and authors chosen among leading scientists active in the field and will have the form of full manuscript single or multiauthored, and of a coherent collection of chapters-reviews edited by one or more leading scientists to cover a given topics. A Scientific Committee formed by Wolfgang Knoll (Max Planck Institute Mainz), Joshua LaBaer (Harvard University, Boston), Michael Kirpichnikov (Moscow University) and Christian Riekel (ESRF, Grenoble) has been established by the Publisher to act as an Editorial Board to discuss with myself as Series Editor for the purpose of sourcing and peer-reviewing manuscripts and providing advice on the series of future high quality Volumes.
Readership
Researchers and students in nanobiotechnology and nanobiosciences fields.
About the Authors
Dr. Joshua LaBaer is one of the nation’s foremost investigators in the rapidly expanding field of personalized medicine. Formerly director of the Harvard Institute of Proteomics (HIP), he was recently recruited to ASU’s Biodesign Institute as the first Piper Chair in Personalized Medicine.
Dr. LaBaer’s efforts involve leveraging the Center’s formidable resources for the discovery and validation of biomarkers—unique molecular fingerprints of disease—which can provide early warning for those at risk of major illnesses, including cancer and diabetes. This work is carried out in conjunction with the Partnership for Personalized Medicine, a multi-institution effort that includes the Translational Genomics Research Institute (TGen) in Phoenix and the Fred Hutchinson Cancer Research Institute in Seattle.
Dr. LaBaer completed his internship and residency at the Brigham and Women’s Hospital and a clinical fellowship in Oncology at the Dana-Farber Cancer Institute, both in Boston. He is a board certified physician in Internal Medicine and Medical Oncology and was an Instructor and Clinical Fellow in Medicine at Harvard Medical School. He has contributed more than 60 original research publications, reviews and chapters. Dr. LaBaer is an associate editor of the Journal of Proteome Research, Analytical Biochemistry, and a member of the Scientific Advisory Boards for the Proteome Society, Promega Corporation, Lumera-Plexera Corporation, Barnett Institute, and a founding member of the Human Proteome Organization.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
